Ketoprofen

A to Z Drug Facts

Ketoprofen

  Action
  Indications
  Contraindications
  Route/Dosage
  Interactions
  Lab Test Interferences
  Adverse Reactions
  Precautions
Patient Care Considerations
  Administration/Storage
  Assessment/Interventions
  Patient/Family Education


(KEY-toe-PRO-fen)
Orudis, Orudis KT, Oruvail,  APO-Keto, APO-Keto-E, APO-Keto SR, Novo-Keto, Novo-Keto-EC, Nu-Ketoprofen, Nu-Ketoprofen-E, Orafen, Orudis E, Orudis SR, PMS-Ketoprofen, PMS-Ketoprofen-E, Rhodis, Rhodis-EC, Rhodis SR, Rhovail
Class: Analgesic/NSAID

 Action Decreases inflammation, pain and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.

 Indications Treatment of rheumatoid arthritis, osteoarthritis, mild to moderate pain, primary dysmenorrhea.

Sustained-release form, only: Treatment of rheumatoid arthritis and osteoarthritis. OTC Use: Temporary relief of minor aches and pains associated with common cold, headache, toothache, muscular aches, backache, minor arthritis pain, menstrual cramps, and reduction of fever. Unlabeled use(s): Treatment of juvenile rheumatoid arthritis, sunburn, migraine prophylaxis.

 Contraindications Patients in whom aspirin, iodides or any NSAID has caused allergic-type reactions.

 Route/Dosage

Rheumatoid or Osteoarthritis

ADULTS: PO 75 mg tid or 50 mg qid; do not exceed 300 mg/day. Maintenance dose: Reduce initial dosage to 75 to 150 mg/day in elderly or disabled patients or patients with renal impairment. Sustained-release capsule: 200 mg once daily can be used in patients already stabilized on that dose.

Mild to Moderate Pain, Primary Dysmenorrhea

ADULTS: PO 25 to 50 mg q 6 to 8 hr prn; do not exceed 300 mg/day.

Mild-To-Severe Renal Function Impairment

PO Maximum recommended total daily dose is 150 mg. In patients with a more severe renal impairment (GFR < 25 ml/min or end-stage renal impairment), the maximum total daily dose should not exceed 100 mg.

Hepatic Function Impairment

PO For patients with impaired liver function and serum albumin concentration < 3.5 g/dl, the maximum initial total daily dose shoudl be 100 mg.

OTC Use

ADULTS: PO 12.5 mg with a full glass of liquid q 4 to 6 hr. If pain or fever persists after 1 hour, follow with 12.5 mg. Do not exceed 25 mg in a 4- to 6-hr period or 75 mg in a 24–hour period. Use the smallest effective dose. CHILDREN: PO Do not give to those < 16 yr unless directed by a physician.

 Interactions

Anticoagulants: Increased risk of gastric erosion and bleeding. Aspirin: Additive GI toxicity. Cyclosporine: Nephrotoxicity of both agents may be increased. Lithium: Serum lithium levels may be increased. Methotrexate: Increased methotrexate levels.

 Lab Test Interferences May prolong bleeding time.

 Adverse Reactions

CV: Peripheral edema; fluid retention; CHF. CNS: Headache; dizziness; lightheadedness; drowsiness; vertigo. DERM: Rash; pruritus. EENT: Visual disturbances; stomatitis. GI: Peptic ulcer; GI bleeding; dyspepsia; nausea; diarrhea; constipation; abdominal pain; flatulence; anorexia; vomiting. GU: Menorrhagia. RESP: Bronchospasm; laryngeal edema; rhinitis; dyspnea.

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Elderly: Increased risk of adverse reactions. GI: Bleeding, ulceration or perforation can occur at any time, with or without warning symptoms. GU: Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia and renal papillary necrosis may occur. Hepatic impairment: Avoid sustained-release product. Hypersensitivity: May occur; use caution in aspirin-sensitive individuals because of possible cross-sensitivity. Renal impairment: Lower doses may be necessary.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  Drowsiness, dizziness, confusion, disorientation, lethargy, numbness, vomiting, gastric irritation, nausea, abdominal pain, headache, tinnitus, convulsions, acute renal failure

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts